Biosimilars – Now a reality even for complex biologics

Tuesday 20 June 2017

Biosimilars: now a reality, even for complex biologics

Biosimilars have been a hot topic among healthcare investors for a few years now and should further take center stage over the next five years as eight out the Top 10 bestselling therapies worldwide will face biosimilar competition. Starting late but having all the relevant expertise and production know-how Biotech companies have partnered with large Pharmaceutical groups to develop biosimilars. While the BPCI Act within Obamacare set a regulatory framework for biosimilars to be approved by the US FDA, its different provisions had first to be battled in court for the law to take shape. This is now almost done.

Read more